Announced
Financials
Tags
Italy
Pending
cell therapy
Biotechnology
Tender Offer
Single Bidder
gene therapy
Pharmaceuticals
Acquisition
Friendly
Majority
Public
Cross Border
Synopsis
AGC, a global contract development and manufacturing organization, offered to acquire Molmed, a biotechnology company, for $267m. AGC offered $0.577 per Molmed share, the equivalent of a premium of 110.3% compared to the stock’s closing price on March 16.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.